Its owners
Hormone Research in Paediatrics, 53(6), 274278
Compounding BPC-157: A regulatory loophole In a statement, Health Canada said "BPC157 has not been authorized, its safety, efficacy, and quality have not been assessed and there is limited scientific evidence to support its use, including a lack of established human dosing protocols." In addition, the regulator says BPC-157 is not approved for use in any NHPs in any form, including oral and injectable, but it can still be compounded for topical use or oral administration as an NHP
It's not a magic solution
Commenters also indicated that an MAO's payment methodology might bundle different cases together such that some cases within an MS-DRG are paid at one rate and others that map to that same MS-DRG are paid at a different rate or such that a single rate is applied to a range of discharges that map to multiple MS-DRGs
Every batch of Astra Labs BPC-157 TB-500 10mg peptide is independently third-party tested by Janoshik Analytical